Last Updated : May 1, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Xalkori | Crizotinib | Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xalkori | Crizotinib | First Line ALK Positive Advanced NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xarelto | Rivaroxaban | Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xarelto | Rivaroxaban | Venous thromboembolism, prevention | N/A | Complete | ||
| Xarelto | Rivaroxaban | Atrial fibrillation, stroke prevention | List with clinical criteria and/or conditions | Complete | ||
| Xarelto | Rivaroxaban | Deep-vein thrombosis without symptomatic pulmonary embolism | List with clinical criteria and/or conditions | Complete | ||
| Xarelto | Rivaroxaban | Deep-vein thrombosis without symptomatic pulmonary embolism | Complete | |||
| Xarelto | Rivaroxaban | List with clinical criteria and/or conditions | Complete | |||
| Xarelto | Rivaroxaban | Venous thromboembolic events, pulmonary embolism | List with criteria/condition | Complete | ||
| Xarelto | Rivaroxaban | Thromboembolism (venous), prevention | List with clinical criteria and/or conditions | Complete |
Last Updated : May 1, 2024